Patents by Inventor Frederic BIENVENU

Frederic BIENVENU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220348919
    Abstract: The invention relates to a nucleic acid molecule comprising: a. a first region comprising a nucleic acid sequence coding for the protein Cyclin D1, also called CCND1, said first region being controlled by means allowing the expression of said protein, and b. at least one second region, said second region comprising essentially a sequence from 14 to 59 nucleic acids, said second region corresponding to a transcribed region of a gene, said second region containing at least a genetic modification compared to the same region of the corresponding wild-type version of said gene, said second region being genetically isolated from the means allowing the expression of said protein such that said second region is not translated into a peptide.
    Type: Application
    Filed: May 12, 2022
    Publication date: November 3, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventor: Frederic BIENVENU
  • Patent number: 11306361
    Abstract: The invention relates to a method for the prognosis a person's susceptibility to environmental stress. The method includes: a step of determining the sequence for initiating the translation of at least one of the genes from the CCND family, and a step of quantifying the expression of the protein encoded by said gene, the translation initiation sequence of which was sequenced in the previous step, and comparing said expression with the expression level of said protein from a reference sample.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: April 19, 2022
    Inventor: Frederic Bienvenu
  • Publication number: 20190345212
    Abstract: The invention relates to a nucleic acid molecule comprising: a. a first region comprising a nucleic acid sequence coding M for the protein Cyclin D1, also called CCND1, said first region being controlled by means allowing the expression of said protein, and b. at least one second region, said second region comprising essentially a sequence from 14 to 59 nucleic acids, said second region corresponding to a transcribed region of a gene, said second region containing at least a genetic modification compared to the same region of the corresponding wild-type version of said gene, said second region being genetically isolated from the means allowing the expression of said protein such that said second region is not translated into a peptide.
    Type: Application
    Filed: January 18, 2018
    Publication date: November 14, 2019
    Inventor: Frederic BIENVENU
  • Publication number: 20180202002
    Abstract: The invention relates to a method for the prognosis a person's susceptibility to environmental stress. The method includes: a step of determining the sequence for initiating the translation of at least one of the genes from the CCND family, and a step of quantifying the expression of the protein encoded by said gene, the translation initiation sequence of which was sequenced in the previous step, and comparing said expression with the expression level of said protein from a reference sample.
    Type: Application
    Filed: July 18, 2016
    Publication date: July 19, 2018
    Inventor: Frederic BIENVENU
  • Publication number: 20170298351
    Abstract: A method for screening interfering nucleic acids enhancing the expression or the activity of expressed gene sequences is described. The method includes a step of introducing, into a cell, a hybrid nucleic acid molecule having: a first non-coding sequence intended to initiate translation; a second sequence complementary to the interfering nucleic acids to be screened; and, optionally, a third nucleotide sequence encoding at least one pre-determined peptide, the first sequence being modified such that the translation level of the at least one peptide is reduced by at least 10%.
    Type: Application
    Filed: September 28, 2015
    Publication date: October 19, 2017
    Inventor: Frédéric Bienvenu